HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

November 2021

The State of Biomarkers in Multiple Sclerosis

November 27, 2021


As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.

Exercise Training and Multiple Sclerosis

November 26, 2021


In line with the push for more comprehensive care, literature suggests that patients with multiple sclerosis benefit from physical therapy interventions to help manage disease symptoms.

Tolebrutinib Adds to the Growing Momentum of BTK Inhibitors in MS

November 26, 2021

Clinical Trial Focus

The Bruton tyrosine kinase inhibitor has been evaluated in 2 phase 3 trials, GEMINI 1 and GEMINI 2 (NCT04410978; NCT04410991), in patients with relapsing-remitting and relapsing secondary progressive MS.

Advanced Practice Providers’ Perspectives on Optimal Multiple Sclerosis Management

November 25, 2021

NeurologyLive Peer Exchange

In a NeurologyLive® Peer Exchange series, experts on the care of patients with multiple sclerosis offer recommendations for selecting and sequencing therapies used to treat patients with relapsing disease.

Moving Toward a More Personalized MS Treatment Journey

November 25, 2021

Letter From the Editor

The field of MS is shifting focus to issues such as understanding and tracking disease progression, approaches to treatment initiation, and the roles of diet and exercise in pathogenesis and disease course.

Bruce Cree, MD, PhD, on the Historically Fast Progress Made in NMOSD Care

August 25, 2021

Clinical Viewpoint

The clinical research director of the UCSF Multiple Sclerosis Center shared his perspective on the history of clinical care for neuromyelitis optica spectrum disorder in light of 3 recent FDA approvals.